Pacer Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Pacer Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20K	Buy	+1,361	New	+$18.9K	﹤0.01%	2255

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Pacer Advisors's CRVS Position: Q2 2026 in Review

Pacer Advisors opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 1,361 shares worth $20K. The stake represents ﹤0.01% of the portfolio and ranks #2255 among its holdings.

174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Pacer Advisors held 1,361 shares of Corvus Pharmaceuticals worth $20K as of Q2 2026.
Corvus Pharmaceuticals was a new Pacer Advisors position in Q2 2026.
Corvus Pharmaceuticals made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2255 holding.
174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.